Abstracts tagged "Behcet’s syndrome"

Abstract Number: 1796 • 2018 ACR/ARHP Annual Meeting
Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades
Elif Dincses¹, Yesim Ozguler², Didar Ucar³, Yilmaz Ozyazgan⁴, Serdal Ugurlu², Gulen Hatemi², Melike Melikoglu², Sebahattin Yurdakul², Hasan Yazici⁵ and Emire Seyahi², ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁵Istanbul Academic Hospital, Istanbul, Turkey
Background/Purpose: There is some evidence that incident Behcet’s syndrome (BS) might be becoming less severe (1, 2). We compared clinical findings at presentation of BS…
Abstract Number: 1815 • 2018 ACR/ARHP Annual Meeting
Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center
Jiaxin Zhou¹, Jing Shi², Xiuhua Wu², JinJing Liu² and Wenjie Zheng², ¹Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To analyze the clinical features of patients with Behcet’s disease(BD) complicated with aneurysmal lesions. Methods: We retrospectively reviewed the clinical data of patients with…
Abstract Number: 1797 • 2018 ACR/ARHP Annual Meeting
An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome
Yesim Ozguler¹, Elif Dincses², Selim Bakan³, Gulen Hatemi¹, Melike Melikoglu¹, Sebahattin Yurdakul¹, Hasan Yazici¹ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, ISTANBUL, Turkey
Background/Purpose: Pulmonary artery involvement (PAI) is the most common form of arterial involvement in Behçet’s syndrome (BS). A previous survey (1) by our group had…
Abstract Number: 1975 • 2018 ACR/ARHP Annual Meeting
Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations
Mohanad Elfishawi^1,2, Sally Elfishawi³, Ghada Mossallam³, Paul Norman⁴, Jill Hollenbach⁵, Maneesh Misra⁵, Gonzalo Montero Martin⁶, Helma de Bruin⁷, Leos Van de Pasch⁷, Erik Rozemuller⁷, Marcelo Fernandiz-Vina⁶, Adriana Abrudescu⁸ and Khaled Zaky⁹, ¹Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, NY, ²Rheumatology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt, ³Clinical pathology and Immunology laboatory, National Cancer Institute, Cairo University, Cairo, Egypt, ⁴Division of Personalized Medicine and Department of Immunology, University of Colorado School of Medicine, Denver, CO, ⁵Department of Neurology, University of California San Francisco, San Francisco, CA, ⁶Department of Pathology, Stanford University,School of medicine, Palo Alto, CA, ⁷GenDx, Utrecht, Netherlands, ⁸Internal Medicine and Rheumatology, Icahn School of Medicine at Mount Sinai, Queens Hospital center, NYC, NY, ⁹Rheumatology and Rehabilitation, Faculty of medicine, Al-Azhar University, Cairo, Egypt
Background/Purpose: Behçet’s disease is a multisystem disease affecting young adults with variable vessel vasculitis as its underlying pathology. Previous studies in Behçet’s disease linked it…
Abstract Number: 1798 • 2018 ACR/ARHP Annual Meeting
Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients
Yesim Ozguler¹, Zekayi Kutlubay², Atilla Süleyman Dikici³, Melike Melikoglu¹, Cem Mat², Hasan Yazici¹ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey, ³Radiolgy, Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey
Background/Purpose: Formal experience with leg ulcers in Behcet’s syndrome (BS) is limited. It is a relatively rare complication that can be seen during the course…
Abstract Number: 2166 • 2018 ACR/ARHP Annual Meeting
Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review
Iustina Janta¹, Roberto González², Tania Gudu³ and Indalecio Monteagudo¹, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ³University of Medicine Carol Davila Bucuresti, Romania, Bucuresti, Romania
Background/Purpose: Venous thrombosis (VT) is a serious and potentially life-threatening manifestation of Behçet disease (BD). However, there is little evidence of the management of the…
Abstract Number: 2747 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide
Mert Gurcan¹, Sinem Nihal Esatoglu¹, Vedat Hamuryudan¹, Caner Saygin², Didem Saygin³, Serdal Ugurlu⁴, Emire Seyahi¹, Melike Melikoglu¹, Izzet Fresko¹, Sebahattin Yurdakul¹, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Cleveland, OH, ³Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events…
Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Sinem Nihal Esatoglu¹, Fatma Nihan Akkoc¹, Yesim Ozguler¹, Fatma Ozbakir², Okan Kadir Nohut², Dilsen Cevirgen³, Vedat Hamuryudan¹, Ibrahim Hatemi⁴, Aykut Ferhat Celik⁵, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Central Research Laboratory, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of and Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…
Abstract Number: 77 • 2017 ACR/ARHP Annual Meeting
Platelets Induce IL-1b Production in Human Monocytes through NLRP3 Inflammasome Activation
Shota Nakano¹, Hiroki Mitoma¹, Shotaro Kawano¹, Shoichiro Inokuchi², Masahiro Ayano¹, Yasutaka Kimoto³, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi⁴ and Hiroaki Niro⁵, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Recent studies have revealed that platelets play pivotal roles in inflammation in addition to hemostasis. The thrombus induces subsequent local inflammation and reversely the…
Abstract Number: 2775 • 2017 ACR/ARHP Annual Meeting
Critical Role of Neutrophil Extracellular Traps (NETs) in Patients with Behcet’s Disease
Alexandre LE JONCOUR^1,2, Stephane Loyau³, Nicolas Lelay⁴, Marie-Christine Bouton⁵, Antoine Dossier⁶, Anne-Claire Desbois⁷, Fanny Domont⁸, Thomas Papo⁹, Martine Jandrot-Perrus⁵, Patrice Cacoub¹⁰, Nadine Ajzenberg⁵, David saadoun⁷ and Yacine Boulaftali², ¹Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DHU i2B), F-75005, Paris, France., National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France, ²INSERM 1148, CHU Xavier Bichat, paris, France, ³Unité INSERM 1148, CHU Xavier Bichat, Faris, France, ⁴2. Unité INSERM 1148, CHU Xavier Bichat, paris, France, ⁵Unité INSERM 1148, CHU Xavier Bichat, paris, France, ⁶3. Service de Médecine Interne, CHU Xavier Bichat, paris, France, ⁷Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France, ⁸Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, paris, France, ⁹Service de Médecine Interne, CHU Xavier Bichat, Paris, France, ¹⁰Département de Médecine Interne et Immunologie Clinique, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France
Background/Purpose: Behçet's disease (BD) is a chronic systemic vasculitis characterised by muco-cutaneous, ocular, gastrointestinal, cerebral recurrent lesions. Venous thrombosis, is a frequent and life-threatening complication.…
Abstract Number: 1075 • 2017 ACR/ARHP Annual Meeting
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor and Cytotoxic Potential of NK Cells in Patients with Behcet Disease
Martina Bonacini¹, Stefania Croci¹, Alessandra Soriano^2,3, Eleonora Calò¹, Alessandro Zerbini¹, Luca Cimino⁴, Francesco Muratore^2,5, Luigi Fontana⁶, Maria Parmeggiani¹ and Carlo Salvarani^2,5, ¹Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ²Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ³Campus Bio-Medico, University of Rome, Italy, Roma, Italy, ⁴Unit of Ocular Immunology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁵University of Modena and Reggio Emilia, Italy, Modena, Italy, ⁶Unit of Ophthalmology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy
Background/Purpose: Behçhet disease (BD) is a rare, systemic, inflammatory disorder with multiorgan damage and various clinical manifestations such as oral ulcers, genital ulcers and uveitis.…
Abstract Number: 1150 • 2017 ACR/ARHP Annual Meeting
Ocular Involvement Is Exclusive with Genital Ulcer and Skin Lesion in the Early Phase of Behçet’s Disease: Nationwide Japanese Registration.
Nobuyuki Horita¹, Akiko Suwa², Mitsuhiro Takeno³, Takehito Ishido², Yohei Kirino⁴ and Nobuhisa Mizuki⁵, ¹National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Yokohama City University, Yokohama, Japan
Background/Purpose: Behçetfs disease (BD) is a chronic inflammatory syndrome with features of multi-organ involvement and presents with mucocutaneous and ocular symptoms. We have previously found…
Abstract Number: 1151 • 2017 ACR/ARHP Annual Meeting
Clinical Manifestations of BehçEt’s Disease Depending on Sex and Age: Nationwide Japanese Registration
Takehito Ishido¹, Nobuyuki Horita², Mitsuhiro Takeno³, Mizuho Ishido¹, Yohei Kirino⁴ and Nobuhisa Mizuki⁵, ¹Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Yokohama City University, Yokohama, Japan
Background/Purpose: Behçetfs disease (BD) has a broad spectrum of clinical phenotypes. Sex differences in BD presentation has been one of the major topics of BD…
Abstract Number: 1170 • 2017 ACR/ARHP Annual Meeting
High Output Flow Cytometry Array Classifies Subjects with Uveitis Due to Behcet’s Disease and Sarcoidosis
Johannes Nowatzky¹, Ezra Resnick², Julia Manasson³, Cristy Stagnar¹ and Olivier Manches⁴, ¹Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ²Google Inc., New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴EFS Rhône-Alpes-Auvergne "Immunobiology and Immunotherapy in Chronic Diseases", INSERM - French National Institute of Health and Medical Research, Grenoble, France
Background/Purpose: The information content of multi-parametric flow cytometry-based immune-phenotyping experiments is routinely underexploited given the paucity of adequate tools and strategies for large-scale unbiased data…
Abstract Number: 2102 • 2017 ACR/ARHP Annual Meeting
The Difference between International Criteria for BD (ICBD) and the BD Criteria of International Study Group (ISG) in Our Behcet’s Disease (BD) Patients Who Fulfilled Japanese BD Criteria
Tsuyoshi Kobashigawa, Yuki Nanke, Hisashi Yamanaka and Shigeru Kotake, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: In Japan, we have a criteria for BD since 1988. (International Journal of Tissue Reactions. 1988: 10; 59-65.) In Japanese patients diagnosed according to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.